Table 1.

Final models for multivariable analyses of FFP, PFS, DSS, and OS

VariableFFPPFSDSSOS
HR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
Age >60 vs ≤60y 1.39 (0.95-2.02) .090 1.73 (1.26-2.37) .001 2.78 (1.51-5.12) .001 4.31 (2.81-6.61) <.0001 
Male vs female 1.48 (1.03-2.13) .034       
ECOG PS 1-2 vs 0       1.42 (0.95-2.12) .086 
Grade 3A vs 1-2         
Stage IIA vs IA 1.51 (1.00-2.26) .048       
Mass <5 cm vs completely excised 2.86 (1.15-7.13) .024 1.47 (0.85-2.54) .165 3.23 (0.76-13.66) .112   
Mass ≥5 cm vs completely excised 4.01 (1.53-10.49) .005 2.16 (1.16-4.02) .015 4.64 (1.04-20.78) .045   
Extranodal disease vs no extranodal disease 0.63 (0.39-1.03) .064       
Serum LDH elevated vs normal 1.99 (1.05-3.77) .035   3.67 (1.68-8.01) .001   
ISRT vs IRRT         
VariableFFPPFSDSSOS
HR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
Age >60 vs ≤60y 1.39 (0.95-2.02) .090 1.73 (1.26-2.37) .001 2.78 (1.51-5.12) .001 4.31 (2.81-6.61) <.0001 
Male vs female 1.48 (1.03-2.13) .034       
ECOG PS 1-2 vs 0       1.42 (0.95-2.12) .086 
Grade 3A vs 1-2         
Stage IIA vs IA 1.51 (1.00-2.26) .048       
Mass <5 cm vs completely excised 2.86 (1.15-7.13) .024 1.47 (0.85-2.54) .165 3.23 (0.76-13.66) .112   
Mass ≥5 cm vs completely excised 4.01 (1.53-10.49) .005 2.16 (1.16-4.02) .015 4.64 (1.04-20.78) .045   
Extranodal disease vs no extranodal disease 0.63 (0.39-1.03) .064       
Serum LDH elevated vs normal 1.99 (1.05-3.77) .035   3.67 (1.68-8.01) .001   
ISRT vs IRRT         

Empty rows mean that the corresponding variable was not retained in the final model.

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; LDH, lactate dehydrogenase.

View Large